Efficacy of Combination Sofosbuvir, Pegylated-Interferon, and Ribavirin for Treatment of Hepatitis C Virus Genotype 1 Infection in Indonesia
Background: The presence of direct-acting antiviral (DAA) has improved the treatment of HCV infection and making it more preferable than Pegylated-interferon (PegIFN) and Ribavirin (RBV) based treatment. However, treatment with all DAA combination regimen is limited and expensive in low health care...
Main Authors: | Andri Sanityoso Sulaiman, Rino Alvani Gani, Irsan Hasan, Cosmas Rinaldi A Lesmana, Juferdy Kurniawan, Chyntia Olivia Maurine Jasirwan, Kemal Fariz Kalista, Muhammad Yusuf Hanif |
---|---|
Format: | Article |
Language: | English |
Published: |
Interna Publishing
2018-08-01
|
Series: | The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy |
Subjects: | |
Online Access: | http://ina-jghe.com/journal/index.php/jghe/article/view/665/539 |
Similar Items
-
The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
by: Walker DR, et al.
Published: (2015-12-01) -
Sofosbuvir‐based therapies in genotype 2 hepatitis C virus cirrhosis: A real‐life experience with focus on ribavirin dose
by: Carlo Smirne, et al.
Published: (2021-08-01) -
Treatment efficacy and tolerability of Sofosbuvir and Ribavirin for chronic hepatitis C infection in post renal transplant patients – A retrospective single centre study
by: B Kirushnan, et al.
Published: (2016-01-01) -
Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study
by: Young Min Kim, et al.
Published: (2018-09-01) -
Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
by: Jong Eun Yeon
Published: (2018-09-01)